Author:
Haroyan Harut,Ginat Daniel Thomas
Publisher
Springer International Publishing
Reference14 articles.
1. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259–67.
2. American College of Radiology. ACR Committee on drugs and contrast media. ACR manual on contrast media. Version 9. Reston: American College of Radiology; 2013.
3. Bennett CL, Qureshi ZP, Oliver Sartor A, Norris LB, Murday A, Xirasagar S, Thomsen HS. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5(1):82–8.
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–92.
5. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol. 2001;176:1385–8.